BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN15505 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN15505\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07594106-11301@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20301027
DTEND;VALUE=DATE:20301028
SUMMARY:REGN15505: Phase 1/2 readout est. (NCT07594106)
DESCRIPTION:REGN15505\, phase 1/2\, Prostate Cancer.\nStudy: REGN15505 (PSM
 Ax4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in
  Adult Patients With Metastatic Castration-Resistant Prostate Cancer and C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: 27 October 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/regn15505#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07594106
URL:https://assetmemo.bio/drug/regn15505#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
